Mereo BioPharma Group plc (MREO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, MREO scores 39 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 6/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow scores 11/20 (institutional accumulation and options positioning); Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit scores 7/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet scores 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillars are Insider Conviction and Fundamental Cash Engine, which together indicate limited evidence of internal confidence and no free-cash-flow yield to support valuation. The strongest pillar, Whale 13F Flow, is the only one scoring above the midpoint, suggesting institutional positioning is the main supportive element in the rating. For a prospective investor, the upside case rests on institutional accumulation and any catalyst that changes the cash-generation profile; the valuation tradeoff is that the reported operating losses and negative ROIC are not offset by current cash yield. The rating reflects vulnerability rather than a forecast of price direction.

Per the SEC financials, operating income was negative in each reported period, and reported gross margin is 0% and operating margin is -60%, per the market data, while net margin is shown as 68%, a figure that diverges sharply from the negative operating results and is not explained in the source data. ROIC is -35% and FCF yield is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Reported cash declined from $69.8M in FY 2024 to $41.0M in FY 2025, while FCF remained negative in every period shown.

Per the recent news feed, the six items are all tagged as market wire and yellow-flagged, and they are predominantly aggregator or market-summary pieces. The most substantive item is a report that Bank of America disclosed shared voting power in MREO in a passive stake amendment. Other items are market-action summaries, including a report of shares rising 5.82% to $0.29, and a generic Marker Therapeutics listing that is not specific to MREO. The source data contains no clinical, regulatory, or partnership catalyst. Several headlines contain source attributions that are not recognizable news outlets (for example, "https://www.siam.in/" and "https://www.dars.gov.et/" appear as sources), which should be treated with caution. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, there are no upstream or downstream dependencies, no sector correlations, and no proprietary signals recorded. The graph's supply_chain field is NONE and butterfly_links is empty. The source data therefore does not identify 2nd-order bottlenecks. The only sector-level information is the classification in the profile (Health Care / Biotechnology: Pharmaceutical Preparations), and the Roarable RQD rating's Macro Regime Fit pillar notes sector sensitivity with Beta 1.0. A prospective investor should recognize that the absence of mapped links is itself a data limitation rather than evidence of independence.

• What is the company's actual revenue source, given reported revenue of $0.5M in FY 2025 and $0.0M in FY 2024?
• What explains the reported net income figures being positive ($41.9M in FY 2025, $43.3M in FY 2024) while operating income and FCF are negative?
• What is the debt balance, given that debt is listed as N/A in every reported period while Debt/Equity is 0.5?
• What are the specific holders and trade records behind the Whale 13F Flow and Insider Conviction pillar scores?
• What is the status of any clinical, regulatory, or partnership programs that could alter the cash-generation profile?